Santé Ventures | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Santé Ventures/Activity

Santé Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company Kestrel Therapeutics received FDA Fast Track Designation for KST-6051, a potential best-in-class pan-KRAS inhibitor for KRAS-mutant advanced solid tumors.

Kestrel Therapeutics

Kestrel Therapeutics Santé Ventures

sante.comSEP 16, 2026

SEP 16, 2026

Investment

ReEmerge, Inc. exited stealth with an oversubscribed $37M Series A to address chronic cognitive impairment caused by brain injuries.

ReEmerge

ReEmerge Santé Ventures

sante.comSEP 15, 2026

SEP 15, 2026

Milestone

Jaguar LAA, Inc. announced the acquisition of assets related to the Laminar program.

Jaguar LAA

Jaguar LAASanté Ventures

sante.comSEP 14, 2026

SEP 14, 2026

Press

Managing Director Omar Khalil discussed early-stage biotech investing in a published interview.

Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil

Santé Ventures

sante.comAUG 25, 2026

AUG 25, 2026

Investment

RapidPulse secured an oversubscribed $48M Series B to advance clinical development of next-generation stroke aspiration technology.

RapidPulse

RapidPulse Santé Ventures

sante.comJUL 16, 2026

JUL 16, 2026

Essay

Santé published commentary on the resurgence of biotech venture funding.

Biotech Venture Funding Roars Back

Santé Ventures

sante.comJUL 16, 2026

JUL 16, 2026

3 milestones· JUN 2026 – JUL 2026Show all

Milestone

Portfolio company Surgical Safety Technologies rebranded as Aimbient, expanding ambient AI across the procedural environment.

Aimbient

AimbientSanté Ventures

sante.comJUL 15, 2026

JUL 15, 2026

Milestone

Endogenex announced full enrollment of its ReCET clinical study.

Endogenex

Endogenex Santé Ventures

sante.comJUL 7, 2026

JUL 7, 2026

Milestone

Reimagine Care and The Center for Cancer and Blood Disorders partnered to redefine support for patients on advanced cancer therapies.

Reimagine Care

Reimagine Care Santé Ventures

sante.comJUN 23, 2026

JUN 23, 2026

Investment

Endovascular Engineering collected $80 million in funding.

Endovascular Engineering

Endovascular Engineering Santé Ventures

sante.comJUN 22, 2026

JUN 22, 2026

3 milestones· MAY 2026 – JUN 2026Show all

Milestone

Iterion Therapeutics reported first clinical validation of Tegavivint as a targeted therapy for Wnt-driven advanced HCC in an oral presentation at the 2026 ASCO Annual Meeting.

Iterion Therapeutics

Iterion Therapeutics Santé Ventures

sante.comJUN 3, 2026

JUN 3, 2026

Milestone

Sonire Therapeutics completed enrollment in its SUNRISE-I randomized controlled trial of ultrasound-guided HIFU therapy for pancreatic cancer.

Sonire Therapeutics

Sonire TherapeuticsSanté Ventures

sante.comJUN 3, 2026

JUN 3, 2026

Milestone

Accrete Health Partners invested in Revelohealth to strengthen contract performance and reimbursement accuracy.

Revelohealth

Revelohealth Santé Ventures

sante.comMAY 28, 2026

MAY 28, 2026

Press

Reimagine Care's Chief Growth Officer John Elliott was interviewed about the company's at-home cancer care platform.

Reimagine Care interview with Chief Growth Officer John Elliott

Santé Ventures

sante.comMAY 28, 2026

MAY 28, 2026

Page 1 of 2